AAV-based gene therapy products utilize adeno-associated virus (AAV) vectors as delivery vehicles to transfer therapeutic genes into target cells for the treatment of various genetic disorders and diseases. AAV vectors are non-pathogenic viruses that can efficiently infect a wide range of cells and have a low immunogenicity profile, making them suitable candidates for gene therapy applications. In AAV-based gene therapy, the therapeutic gene of interest is inserted into the AAV vector's genome, and the vector is then administered to the patient, typically via intravenous injection or direct injection into the affected tissue. Once inside the target cells, the AAV vector delivers the therapeutic gene, allowing it to be expressed and produce the desired therapeutic protein. AAV-based gene therapy products hold significant promise for the treatment of inherited genetic disorders, as well as acquired diseases such as certain types of cancer and neurodegenerative disorders, offering potential long-term therapeutic benefits with a single administration.

The global AAV-based Gene Therapy Products market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “AAV-based Gene Therapy Products Industry Forecast” looks at past sales and reviews total world AAV-based Gene Therapy Products sales in 2023, providing a comprehensive analysis by region and market sector of projected AAV-based Gene Therapy Products sales for 2024 through 2030. With AAV-based Gene Therapy Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AAV-based Gene Therapy Products industry.

This Insight Report provides a comprehensive analysis of the global AAV-based Gene Therapy Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on AAV-based Gene Therapy Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global AAV-based Gene Therapy Products market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AAV-based Gene Therapy Products and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AAV-based Gene Therapy Products.

United States market for AAV-based Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for AAV-based Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for AAV-based Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key AAV-based Gene Therapy Products players cover:

• uniQure
• Spark Therapeutics
• AveXis (Novartis)
• PTC Therapeutics
• BioMarin

In terms of revenue, the global two largest companies occupied for a share nearly % in 2023. This report presents a comprehensive overview, market shares, and growth opportunities of AAV-based Gene Therapy Products market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• AAV2
• AAV8
• AAV9
• Others

Segmentation by Application:

• Haematology
• Ophthalmology
• Neurology
• Musculoskeletal
• Others

This report also splits the market by region:

• Americas
  • United States
  • Canada
  • Mexico
  • Brazil
• APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
• Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration:

• uniQure
• Spark Therapeutics
• AveXis (Novartis)
• PTC Therapeutics
• BioMarin
• Sarepta Therapeutics
• Roche
• Pfizer
• CSL Behring
• Sangamo Therapeutics
• Biogen
• Freeline Therapeutics
• Coave Therapeutics
• MeiraGTx
• RegenxBio
• Asklepios Biopharmaceutical
• Audentes Therapeutics
• Neurophth
• Belief BioMed

Key Questions Addressed in this Report:

1. What is the 10-year outlook for the global AAV-based Gene Therapy Products market?
2. What factors are driving AAV-based Gene Therapy Products market growth, globally and by region?
3. Which technologies are poised for the fastest growth by market and region?
4. How do AAV-based Gene Therapy Products market opportunities vary by end market size?
5. How does AAV-based Gene Therapy Products break out by Type, by Application?